Langmuir (2004) 20:10436
ng thi gip tng cng chng oxy ha v sn sinh glutathione t nhin Chit xut tr xanh: Giu cht chng oxy ha, h tr lm sng da, tr thm L-Cysteine: Lm p da v ngn nga lo ha u im : Sn phm c cng thc chm sc da c quyn, va dng trng ton thn va y li cc du hiu ca lo ha
(Bifidobacterium lactis BS01, Bifidobacterium breve BR03, Lactobacillus acidophilus LA02, Lactobacillus plantarum LP09, Lactobacillus rhamnosus LR06, Lactobacillus casei LC03, Bifidobacterium bifidum BB01, Streptococcus thermophilus YO8, Lactobacillus plantarum LP01, Lactobacillus rhamnosus LR05, Lactobacillus rhamnosus GG, Bifidobacterium longum BL03, Lactobacillus reuteri LRE02, Lactobacillus salivarius subsp. salivarius CRL1328, Bifidobacterium lactis BA05)
These programs may provide: reduced medication costs temporary medication access during financial hardship additional support services Eligibility requirements often depend on income level, insurance status and country of residence
1 Steno Diabetes Center Copenhagen, Herlev, Denmark, 2 Rigshospitalet, Copenhagen, Denmark, 3 University of Copenhagen, Copenhagen, Denmark, 4 Odense University Hospital, Odense, Denmark, 5 Steno Diabetes Center Odense, Odense, Denmark, 6 Aarhus University, Aarhus, Denmark, 7 Aarhus University Hospital, Aarhus, Denmark, 8 Steno Diabetes Center Aarhus, Aarhus, Denmark, 9 University of Southern Denmark, Odense, Denmark
For clinical bioequivalence studies, method validation is free of cost